Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2

Publication

Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2

Journal Paper/Review - May 10, 2018

Gilgen Nicole, Butter Christian, Bruch Leonhard, Kaiser Christoph, Hoffmann Andreas, Rickenbacher Peter, Mueller Christian, Stephan Frank-Peter, Coslovsky Michael, Jeger Raban, Krackhardt Florian, Zweiker Robert, Farah Ahmed, Scheller Bruno, Ohlow Marc-Alexander, Mangner Norman, Weilenmann Daniel, Wöhrle Jochen, Jamshidi Peiman, Leibundgut Gregor, Möbius-Winkler Sven, BASKET-SMALL 2 Investigators

Citation

Gilgen N, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan F, Coslovsky M, Jeger R, Krackhardt F, Zweiker R, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. Clin Cardiol 2018; 41:569-575.

Type

Journal Paper/Review (English)

Journal

Clin Cardiol 2018; 41

Publication Date

May 10, 2018

Issn Electronic

1932-8737

Pages

569-575

Brief description/objective

The treatment of coronary small vessel disease (SVD) remains an unresolved issue. Drug-eluting stents (DES) have limited efficacy due to increased rates of instent-restenosis, mainly caused by late lumen loss. Drug-coated balloons (DCB) are a promising technique because native vessels remain structurally unchanged. Basel Stent Kosten-Effektivitäts Trial: Drug-Coated Balloons vs. Drug-Eluting Stents in Small Vessel Interventions (BASKET-SMALL 2) is a multicenter, randomized, controlled, noninferiority trial of DCB vs DES in native SVD for clinical endpoints. Seven hundred fifty-eight patients with de novo lesions in vessels <3 mm in diameter and an indication for percutaneous coronary intervention such as stable angina pectoris, silent ischemia, or acute coronary syndromes are randomized 1:1 to angioplasty with DCB vs implantation of a DES after successful initial balloon angioplasty. The primary endpoint is the combination of cardiac death, nonfatal myocardial infarction, and target-vessel revascularization up to 1 year. Secondary endpoints include stent thrombosis, Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding, and long-term outcome up to 3 years. Based on clinical endpoints after 1 year, we plan to assess the noninferiority of DCB compared to DES in patients undergoing primary percutaneous coronary intervention for SVD. Results will be available in the second half of 2018. This study will compare DCB and DES regarding long-term safety and efficacy for the treatment of SVD in a large all-comer population.